Skip to main content

Table 1 Patient demographics, disease characteristics and therapy.

From: A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects

Number of patients N = 65 Surgical margins  
Mean age (range) in yrs 69(53 - 86) Negative 62 (95%)
Tumour class(AJCC)   Positive 1 (2%)
pTis 3 (5%) Close 2 (3%)
pT1a 4 (6%) Hormonal status  
pT1b 10 (15%) HR positive 60 (92%)
pT1c 34 (52%) HR negative 5 (8%)
pT2 14 (22%) Hormone therapy  
Max tumour diam. (range) mm 3 - 30 Yes 57 (88%)
Grading   No 5 (13%)
G1 12 (18%) Chemotherapy 9 (14%)
G2 39 (60%)   
G3 14 (22%)   
Proliferative index (Ki67) %    
≤ 15 39 (60%)   
> 15 26 (40%)   
Nodal status    
pN0 58 (89%)   
pN1(a) 7 (11%)